公开(公告)号：US08911733B2

公开(公告)日：2014-12-16

申请号：US11441828

申请日：2006-05-26

Applicant: Vernon Michael Holers ,  Joshua M. Thurman ,  Stephen Tomlinson ,  Philip F. Stahel

Inventor： Vernon Michael Holers ,  Joshua M. Thurman ,  Stephen Tomlinson ,  Philip F. Stahel

IPC: A61K39/395 ,  C07K16/42 ,  C07K16/18 ,  A61K39/00

CPC classification number: C07K16/42 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/76 ,  C07K2319/30

Abstract: Disclosed is the use of agents and compositions that selectively inhibit the alternative complement pathway for the inhibiting or treating physiological damage resulting from traumatic brain injury (TBI), spinal cord injury (SCI), or related conditions. Preferred reagents for use in inhibition of damage resulting from TBI or SCI include those that inhibit factor B, with anti-factor B antibodies representing a particularly preferred agent.

Abstract translation: 公开了使用选择性抑制替代补体途径用于抑制或治疗由创伤性脑损伤（TBI），脊髓损伤（SCI）或相关病症引起的生理损伤的药剂和组合物。 用于抑制由TBI或SCI引起的损伤的优选试剂包括抑制因子B的那些，抗因子B抗体代表特别优选的药剂。

公开(公告)号：US08852932B2

公开(公告)日：2014-10-07

申请号：US13529172

申请日：2012-06-21

Applicant: Gabor Forgacs ,  Karoly Jakab ,  Adrian Neagu ,  Vladimir Mironov

Inventor： Gabor Forgacs ,  Karoly Jakab ,  Adrian Neagu ,  Vladimir Mironov

IPC: C12N5/07 ,  C12N11/12 ,  C12N5/02 ,  B29C67/00 ,  C12M1/00 ,  C12M3/00 ,  C12N11/00 ,  C12N5/00 ,  B29L31/00 ,  B29K105/00

CPC classification number: C12N5/0062 ,  B29C64/112 ,  B29C64/209 ,  B29C64/386 ,  B29C64/393 ,  B29K2033/26 ,  B29K2105/0035 ,  B29K2105/0061 ,  B29L2031/7532 ,  B33Y10/00 ,  B33Y30/00 ,  B33Y50/02 ,  B33Y70/00 ,  B33Y80/00 ,  C12M21/08 ,  C12M33/12 ,  C12M41/48 ,  C12M47/00 ,  C12M47/02 ,  C12N5/0697

Abstract: A method of making engineered tissue from a plurality of cell aggregates is disclosed. A cell suspension is centrifuged. The resulting pellet is extruded through an orifice, and the extruded pellet is cut into pieces to produce cell aggregates. A plurality of the cell aggregates are printed in a pattern, and allowed to fuse to form a desired three-dimensional engineered tissue structure. Modeling methods predict the structural evolution of fusing cell aggregates for combinations of cell type to enable selection of organ printing process parameters for use in producing an engineered tissue having a desired three-dimensional structure.

Abstract translation: 公开了一种从多个细胞聚集体制备工程组织的方法。 将细胞悬浮液离心。 将所得颗粒通过孔挤出，将挤出的颗粒切成块以产生细胞聚集体。 多个细胞聚集体以图案印刷，并允许熔合以形成所需的三维工程组织结构。 建模方法预测用于细胞类型组合的融合细胞聚集体的结构演变，以使得能够选择用于生产具有期望的三维结构的工程化组织的器官印刷工艺参数。

公开(公告)号：US20140275178A1

公开(公告)日：2014-09-18

申请号：US13798421

申请日：2013-03-13

Applicant: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT

Inventor： Craig C. BEESON ,  Christopher C. LINDSEY ,  Yuri K. PETERSON ,  Baerbel ROHRER

IPC: C07D277/56 ,  C07D417/04

CPC classification number: C07D277/56 ,  C07D417/04

Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of degenerative diseases and disorders.

Abstract translation: 本文提供式（I）的化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗退行性疾病和病症。

公开(公告)号：US08633028B2

公开(公告)日：2014-01-21

申请号：US10883009

申请日：2004-07-02

Applicant: Paul S. Gross ,  Gregory Warr ,  Robert Chapman ,  Craig Browdy ,  Javier Robalino

Inventor： Paul S. Gross ,  Gregory Warr ,  Robert Chapman ,  Craig Browdy ,  Javier Robalino

IPC: A61K48/00 ,  C12N15/85 ,  C12Q1/68

CPC classification number: C12N15/1131 ,  A61K2039/55561 ,  C12N15/117 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/17 ,  C12N2310/53 ,  Y02A50/403

Abstract: Methods for inducing systemic, non-specific and/or sequence specific immune responses in invertebrates, e.g., marine invertebrates such as mollusks, porifera, ctenophora, echinodermas, marine worms, cnideria and preferably crustaceans, by the administration of at least one dsRNA, that confers immunity against a pathogen, or modulates expression of gene that affects growth, reproduction, and general health or “robustness” are provided. Also provided are methods of identifying invertebrate genes, e.g., crustacean genes, the expression of which is involved in the induction of non-specific (systemic) immune responses against pathogens. Also disclosed are preferred delivery systems and methods for stably administering at least one dsRNA to a crustacean whereby the dsRNA is administered via injection, immersion, in a feed or nutrient medium or comprised in a microorganism, e.g., yeast or microalgae, that expresses said dsRNA and is ingestible by said crustacean, e.g., a shrimp.

Abstract translation: 通过施用至少一种dsRNA，在无脊椎动物中诱导全身，非特异性和/或序列特异性免疫应答的方法，例如海洋无脊椎动物如软体动物，porifera，ctenophora，棘皮动物，海洋蠕虫，cnideria和优选甲壳类动物， 赋予对病原体的免疫力，或调节影响生长，繁殖和一般健康或“健壮性”的基因的表达。 还提供了鉴定无脊椎动物基因的方法，例如甲壳类动物基因，其表达参与诱导针对病原体的非特异性（全身）免疫应答。 还公开了用于将至少一种dsRNA稳定施用于甲壳动物的优选递送系统和方法，由此dsRNA通过注射，浸渍，饲料或营养培养基或包含在表达所述dsRNA的微生物（例如酵母或微藻）中施用 并且被甲壳类动物摄入，例如虾。

公开(公告)号：US20130274206A1

公开(公告)日：2013-10-17

申请号：US13842506

申请日：2013-03-15

Applicant: MUSC Foundation for Research Development

Inventor： Gautam Ghatnekar

IPC: C07K14/47 ,  C07K7/06 ,  C07K7/08 ,  C07K5/10

CPC classification number: A61K38/177 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1709 ,  A61K38/1767 ,  A61K45/06 ,  A61L31/08 ,  A61L2430/34 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/43581 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/01 ,  C07K2319/10

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

Abstract translation: 本文提供了用于促进受试者组织损伤后伤口愈合和组织再生的组合物和方法。

公开(公告)号：US20130177628A1

公开(公告)日：2013-07-11

申请号：US13715626

申请日：2012-12-14

Applicant: Gautam GHATNEKAR ,  Tuan Elstrom

Inventor： Gautam GHATNEKAR ,  Tuan Elstrom

IPC: A61K38/10 ,  A61K38/08

CPC classification number: A61K38/177 ,  A61K38/07 ,  A61K38/08 ,  A61K38/10 ,  A61K38/1709 ,  A61K38/1767 ,  A61K45/06 ,  A61L31/08 ,  A61L2430/34 ,  C07K5/10 ,  C07K7/06 ,  C07K7/08 ,  C07K14/43581 ,  C07K14/47 ,  C07K14/705 ,  C07K2319/01 ,  C07K2319/10

Abstract: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.

公开(公告)号：US08454963B2

公开(公告)日：2013-06-04

申请号：US11116939

申请日：2005-04-28

Applicant: Stephen Tomlinson ,  Richard J. Quigg

Inventor： Stephen Tomlinson ,  Richard J. Quigg

IPC: A61K38/00 ,  C07K16/28 ,  C07K14/705

CPC classification number: C07K14/70596 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00 ,  C07K2319/30

Abstract: Systemic suppression of the complement system has been shown to be effective to treat inflammatory disease, yet at the potential cost of compromising host defense and immune homeostasis. Herein disclosed are methods for antigen-specific targeting of complement inhibitors that show that complement inhibitors targeted to the proximal tubular epithelium protect against tubulointerstitial injury and renal dysfunction in a rat model of nephrosis. It is shown that appropriate targeting of a systemically administered complement inhibitor to a site of disease markedy enhances efficacy and obviates the need to systemically inhibit complement. Additionally, it is shown by specifically inhibiting the terminal pathway of complement, that the membrane attack complex (MAC) plays a key role in proteinuria-induced tubulointerstitial injury, thus establishing the MAC as a valid target for pharmacological intervention in proteinuric disorders. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Abstract translation: 补体系统的系统抑制已被证明是有效治疗炎性疾病，但是潜在的牺牲宿主防御和免疫稳态的代价。 本文公开的是用于补体抑制剂的抗原特异性靶向的方法，其显示针对近端肾小管上皮的补体抑制剂保护肾小管模型中的肾小管间质损伤和肾功能障碍。 已经表明，将系统给药的补体抑制剂适当靶向标记的疾病部位增强功效，并且避免需要系统地抑制补体。 另外，通过特异性抑制补体的末端途径显示，膜攻击复合物（MAC）在蛋白尿诱导的肾小管间质损伤中起关键作用，从而建立MAC作为蛋白质性疾病药理学干预的有效靶标。 所公开的是组合物可以用于通过调节补体系统来治疗病原性疾病和炎性病症的方法。

公开(公告)号：US08445222B2

公开(公告)日：2013-05-21

申请号：US12307985

申请日：2007-07-11

Applicant: Francis G. Spinale ,  Robert E. Stroud ,  Michael R. Zile

Inventor： Francis G. Spinale ,  Robert E. Stroud ,  Michael R. Zile

IPC: C12Q1/37

CPC classification number: C12Q1/37 ,  G01N2333/96486 ,  G01N2800/324 ,  G01N2800/325

Abstract: Disclosed herein are methods of detecting or predicting diastolic heart failure in a subject, comprising identifying a profile of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) from a body fluid of the subject that is associated herein with the existence of likely development of left ventricular dilation (LVD).

Abstract translation: 本文公开了检测或预测受试者的舒张性心力衰竭的方法，包括从与本文相关的受试者的体液识别基质金属蛋白酶（MMP）和基质金属蛋白酶组织抑制剂（TIMPs）的分布，其存在可能 发展左心室扩张（LVD）。

公开(公告)号：US20120014952A1

公开(公告)日：2012-01-19

申请号：US13162479

申请日：2011-06-16

Applicant: Stephen Tomlinson ,  V. Michael Holers

Inventor： Stephen Tomlinson ,  V. Michael Holers

IPC: A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  A61P29/00 ,  A61P31/04 ,  A61P31/10 ,  A61P33/00 ,  A61P35/00 ,  C07K19/00 ,  A61P31/12

CPC classification number: C07K14/70596 ,  A61K38/00 ,  C07K14/705 ,  C07K16/2896 ,  C07K2319/00

Abstract: Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

公开(公告)号：US20120010094A1

公开(公告)日：2012-01-12

申请号：US13128200

申请日：2009-11-04

Applicant: Francis G. Spinale ,  Michael R. Zile ,  Robert E. Stroud

Inventor： Francis G. Spinale ,  Michael R. Zile ,  Robert E. Stroud

IPC: C40B30/04 ,  G01N33/566 ,  G01N33/573 ,  C12Q1/37

CPC classification number: G01N33/6893 ,  G01N2333/4703 ,  G01N2333/52 ,  G01N2333/58 ,  G01N2333/78 ,  G01N2333/8146 ,  G01N2800/325 ,  G01N2800/60

Abstract: Disclosed herein are methods of detecting, monitoring, and predicting left ventricular hypertrophy, congestive heart failure and related conditions by profiling biomarkers.

Abstract translation: 本文公开了通过分析生物标志物检测，监测和预测左心室肥大，充血性心力衰竭和相关病症的方法。